Prevision Medicine Raises $5.4M Seed Round

Qambria

A quantum computer is an accelerator that solves a handful of problems no classical machine can, and it is strongest exactly where classical computing is weakest, so the two belong together in one machine. The GPU proved how this works for AI; Qambria does the same for quantum, turning the quantum processor into a native accelerator inside a standard high-performance computing node: the quantum-accelerated node. The barrier to getting there is classical. A quantum processor has to be scheduled, fed data, and error-corrected in real time, and today that is improvised from general-purpose parts that add latency, cost and complexity. Qambria supplies the classical layer that removes those bottlenecks, a vendor- and modality-neutral infrastructure platform. Our mission is to make quantum computing practical, accessible and deployable at scale: quantum utility today, and quantum advantage as the hardware matures.

Piomic Medical

Piomic Medical is a Swiss ETH Zurich startup and emerging regenerative medtech company pioneering deep tissue regeneration through physical stimulation therapies, with headquarters in Zurich and U.S. operations in Chicago. Our proprietary COMS® platform (Concurrent Optical and Magnetic Stimulation) delivers synergistic stimulation designed to modulate key regenerative pathways, including ion channel signaling, nitric oxide production, and mitochondrial activity, to support cellular metabolism and facilitate tissue repair. Our flagship device, the COMS® One Therapy System, is a portable device for treatment of non-healing wounds, designed for seamless use across hospital, outpatient, and home-care settings. It has received FDA Breakthrough Device Designation and is CE-marked under the EU Medical Device Regulation (MDR). Piomic’s strong and growing clinical portfolio includes two active studies: • MAVERICKS – a randomized, double-blinded FDA IDE pivotal trial in therapy-refractory diabetic foot ulcers in the U.S. • NAZARÉ – a multicenter real-world evidence study evaluating COMS® therapy in chronic vascular leg ulcers across European wound centers. Beyond wound healing, the COMS® platform has potential applications in various other disease areas, such as sports medicine, aesthetics, ophthalmology and infection management. Piomic’s mission is to advance regenerative therapies and improve outcomes for patients with difficult-to-treat conditions worldwide. 𝘙𝘦𝘨𝘶𝘭𝘢𝘵𝘰𝘳𝘺 𝘯𝘰𝘵𝘦: 𝘛𝘩𝘦 𝘊𝘖𝘔𝘚® 𝘖𝘯𝘦 𝘛𝘩𝘦𝘳𝘢𝘱𝘺 𝘚𝘺𝘴𝘵𝘦𝘮 𝘪𝘴 𝘤𝘶𝘳𝘳𝘦𝘯𝘵𝘭𝘺 𝘪𝘯𝘷𝘦𝘴𝘵𝘪𝘨𝘢𝘵𝘪𝘰𝘯𝘢𝘭 𝘢𝘯𝘥 𝘩𝘢𝘴 𝘯𝘰𝘵 𝘺𝘦𝘵 𝘳𝘦𝘤𝘦𝘪𝘷𝘦𝘥 𝘳𝘦𝘨𝘶𝘭𝘢𝘵𝘰𝘳𝘺 𝘢𝘱𝘱𝘳𝘰𝘷𝘢𝘭 𝘪𝘯 𝘵𝘩𝘦 𝘜𝘯𝘪𝘵𝘦𝘥 𝘚𝘵𝘢𝘵𝘦𝘴 𝘰𝘳 𝘊𝘢𝘯𝘢𝘥𝘢.